This concerns financial toxicity theory in oncology care — the concept that the direct and indirect economic burden of cancer treatment (drug costs, out-of-pocket expense, income loss) constitutes a distinct dimension of illness burden that can independently influence a patient's medical decision-making, separate from clinical risk-benefit considerations. It sits within the domain of medical ethics and health-services research on the human/psychosocial side of oncology care, specifically the intersection of cost, patient autonomy, and treatment-initiation timing decisions (e.g., "watch and wait" versus active treatment) in chronic disease management.
This concerns financial toxicity theory in oncology care — the concept that the direct and indirect economic burden of cancer treatment (drug costs, out-of-pocket expense, income loss) constitutes a …